HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
INSP
Inspire Medical Systems, Inc.
INSP's fundamentals are mixed, but it looks cheap: trading at 18x earnings, about a third of its usual 58x. Analysts expect strong earnings growth, though they disagree widely on how much.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
INSP Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Healthy | |
| Healthy | |
| Strong |
INSP's profitability, cash flow and balance sheet are currently healthy, but its revenue is under pressure.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
INSP PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 12x | $39.83 | -34% |
| Current | 18x | $60.54 | — |
| Forward | 43x | $60.54 | — |
| Fair | 58x | $194 | +220% |
| Expensive | 173x | $579 | +857% |
Historical ranges are pointers, not guarantees.
INSP's PE is in its cheap range at 18x. On analysts' estimates for next year's earnings, today's price would be 43x, in its fair range.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
INSP Forward outlook
| Metric | Outlook |
|---|---|
| Strongly deteriorating | |
| Strong growth | |
| Stable | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect INSP's earnings to grow and its profitability to improve, with its revenue holding steady. However, they disagree widely on these estimates.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
INSP Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $1.41 | -58% |
| Q3 2026 | $3.35 | +125% |
| Q2 2026 | $4.53 | +159% |
| Q1 2026 | $4.40 | +101% |
| Q4 2025 | $4.89 | +179% |
| Q3 2025 | $1.49 | +37% |
| Q2 2025 | $1.75 | +775% |
| Q1 2025 | $2.19 | +$2.72 |
| Q4 2024 | $1.75 | +$2.47 |
INSP has the edge over HIMS on earnings quality, reporting a profit while its opponent remains loss making.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over INSP on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS has the edge over INSP on profitability, with a higher operating margin.
INSP Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $206.7M | -7.9% |
| Q2 2026 | $200.6M | -7.6% |
| Q1 2026 | $204.6M | +1.6% |
| Q4 2025 | $269.1M | +12% |
| Q3 2025 | $224.5M | +10% |
| Q2 2025 | $217.1M | +11% |
| Q1 2025 | $201.3M | +23% |
| Q4 2024 | $239.7M | +25% |
INSP's revenue has held roughly level: $207M last quarter, down 7.9% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -14% | -18 points |
| Q2 2026 | -0.3% | +1.3 points |
| Q1 2026 | -0.6% | +0.2 points |
| Q4 2025 | 17% | +3.8 points |
| Q3 2025 | 4.3% | -2.8 points |
| Q2 2025 | -1.5% | -4.1 points |
| Q1 2025 | -0.7% | +8.5 points |
| Q4 2024 | 13% | +8.5 points |
INSP's operating margin was −14% last quarter, down 18 points from the same quarter a year ago.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over INSP on cash flow, with more consistent year-over-year improvement.
INSP Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $38.9M | -33% |
| Q2 2026 | $14.1M | +$20.4M |
| Q1 2026 | $3.1M | +$18.2M |
| Q4 2025 | $41.8M | -33% |
| Q3 2025 | $58.1M | +31% |
| Q2 2025 | -$6.3M | +$6.2M |
| Q1 2025 | -$15.1M | -$12.3M |
| Q4 2024 | $62.2M | +573% |
INSP generated $98M in free cash flow over the past year, about the same as the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over INSP on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
INSP Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -11.5K shares |
| 1 year | -2.3% | -671K shares |
| 3 years | -1.5% | -437K shares |
| 5 years | +6% | +1.6M shares |
| Available history | +22% | +5.1M shares |
INSP has 29M diluted shares, down 2.3% from a year ago, with $50M in buybacks over the past year.
| Quarter | Spent |
|---|---|
| Q3 2026 | — |
| Q2 2026 | — |
| Q1 2026 | — |
| Q4 2025 | $50M |
| Q3 2025 | $50M |
| Q2 2025 | — |
| Q1 2025 | $75M |
INSP spent $50M buying back its own shares over the past year.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
INSP Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -5.6x | Net Cash |
| Q2 2026 | -1.8x | Net Cash |
| Q1 2026 | -1.5x | Net Cash |
| Q4 2025 | -1.6x | Net Cash |
| Q3 2025 | -2.3x | Net Cash |
| Q2 2025 | -2.1x | Net Cash |
| Q1 2025 | -0.9x | Net Cash |
| Q4 2024 | -3.5x | Net Cash |
INSP has more cash than debt.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
INSP Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 46.7 | Neutral |
| Stochastic | 44.4 | Neutral |
INSP's weekly RSI is 47 (neutral) and its Stochastic is 44 (neutral).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
INSP PE vs Healthcare Sector
| Metric | INSP | Sector median | Relative |
|---|---|---|---|
| PE | 18x | 26x | 30% below |
| PE % | 32 | 29 | 3 pts above |
INSP is trading at 18x earnings, a 30% discount to the Healthcare sector's median of 26x.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
INSP Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $67.7 | 11% below |
| 20 week MA | $62.2 | 2.7% below |
| 50 week MA | $64.8 | 6.5% below |
| 100 week MA | $99.3 | 39% below |
| 200 week MA | $156.2 | 61% below |
INSP is in a downtrend: it's below all five of its weekly moving averages, and 61% below its 200-week average.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.
INSP Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $74.2 | $190.7 | +157% |
| 2021 | $190.7 | $239.2 | +25% |
| 2022 | $239.2 | $257.5 | +7.7% |
| 2023 | $257.5 | $203.4 | -21% |
| 2024 | $203.4 | $188.5 | -7.3% |
| 2025 | $188.5 | $95.5 | -49% |
| 2026 YTD | $95.5 | $60.5 | -37% |
INSP has the edge over HIMS on returns for 2026, with the stronger performance.